Latest News

Full results from the phase 3 TEMPO-2 trial, published in Lancet Neurology, showed that flexible-dose tavapadon significantly improved motor symptoms and daily function in people with early Parkinson disease.

A recently published phase 2 trial showed that CBD/THC cannabis oil failed to ease chronic pain or nonmotor symptoms versus placebo among patients with Parkinson disease.

Kyle Marden, MD, sports neurologist and medical director of the Concussion and Sports Neurology Program at Northwestern Medicine, discusses emerging developments in concussion diagnosis and management, ongoing challenges in the field, and the future of individualized care.

A narrative review highlighted the limited pediatric-specific evidence supporting headache treatment after stroke and in cerebrovascular disorders, emphasizing consideration of vascular pathophysiology, cerebral perfusion, and collateral flow when selecting therapies.

David Stamler, MD, Chief Executive Officer of Alterity Therapeutics, discusses the FDA's alignment on the pivotal Phase 3 program for ATH434 in multiple system atrophy and what a successful trial could mean for a disease with no approved disease-modifying therapies.

Teva Pharmaceuticals' ecopipam receives priority review by the FDA, supported by studies showing sustained tic control among pediatric patients with Tourette syndrome.

The FDA granted Fast Track designation to Acadia Pharmaceuticals’ investigational remlifanserin for hallucinations and delusions associated with Alzheimer disease psychosis.

The cerebrovascular neurosurgeon at University Medical Center New Orleans discussed performing the first THUNDERBOLT stroke thrombectomy in the United States and what computer-assisted vacuum thrombectomy offers over traditional aspiration.

Alexandra Bonner, MD, a pediatric neuromuscular neurologist at Cleveland Clinic, discussed why real-time communication between specialists is the hardest part of multidisciplinary care for patients with spinal muscular atrophy.

Alexandra Bonner, MD, a pediatric neuromuscular neurologist at Cleveland Clinic, discussed which specialties are essential to a spinal muscular atrophy care team and why anticipating future needs has become central to the work.

A recently published case study highlights a 17-year-old patient with Duchenne muscular dystrophy who experienced acute and delayed cardiac toxic effects under delandistrogene moxeparvovec treatment, with tissue analyses showing low-level, heterogeneous microdystrophin expression.

Stacey Tarrant, RD, LDN, discusses how earlier treatment alongside disease-modifying therapies have changed nutritional priorities in spinal muscular atrophy, including the need to optimize growth, strength, function, and body composition.

The new data from ALKIVIA marks the first phase 3 study to show statistically significant, clinically meaningful improvement in immune-mediated necrotizing myopathy, a subtype with no approved therapy.